Position in DNLI
as of Jun 30, 2026
· filed Aug 11, 2026
Position Value
$1,706,984
+$412,578 QoQ
Shares Held
66,368
-1.6% QoQ
Ownership
0.042%
of shares outstanding
% of Portfolio
0.52%
of 13F equity value
Holder Rank
#102
of 290 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in DNLI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 20261492 Capital Management LLC holds $24,471,164 across 11 Biotechnology names. DNLI ranks #6 (7.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | AXSM |
Axsome Therapeutics, Inc.
|
29,307 | $7,173,474 | |
| 2 | KURA |
Kura Oncology, Inc.
|
467,153 | $5,124,668 | |
| 3 | ARQT |
Arcutis Biotherapeutics, Inc.
|
116,211 | $3,047,052 | |
| 4 | VKTX |
Viking Therapeutics, Inc.
|
55,723 | $2,173,754 | |
| 5 | MNKD |
Mannkind Corp
|
481,722 | $2,052,135 | |
| 6 | DNLI |
Denali Therapeutics Inc.
This page
|
66,368 | $1,706,984 | |
| 7 | SNDX |
Syndax Pharmaceuticals Inc
|
66,997 | $1,464,554 | |
| 8 | FENC |
Fennec Pharmaceuticals Inc.
|
65,149 | $700,351 |
All Filings in DNLI
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,706,984 | 66,368 | Shares | Sole | 2026-08-11 | |
| 2026-03-31 | $1,294,406 | 67,417 | Shares | Sole | 2026-04-22 | |
| 2025-12-31 | $1,114,210 | 67,487 | Shares | Sole | 2026-02-10 | |
| No filing history on record for this holder in this stock. | ||||||